Medical devices, healthcare technology and the business of care
PMA approval · P110042

SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM

BOSTON SCIENTIFIC CORPORATION · Decision date Sep 28, 2012

MEDTECHLEDGER EXPLANATIONP110042

What did the FDA approve?

The FDA database entry records an original PMA approval for the Subcutaneous Implantable Defibrillator (S-ICD) System, dated September 28, 2012. The approved indication is defibrillation therapy for life-threatening ventricular tachyarrhythmias in patients who do not have symptomatic bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring ventricular tachycardia that is reliably terminated with antitachycardia pacing.

The applicant is Boston Scientific Corporation, and the device is classified under product code LWS as an implantable cardioverter defibrillator (non-CRT) in the cardiovascular specialty. The entry contains no supplement type or supplement reason, and the statement does not report clinical outcomes or comparative safety data.

FDA approval order statement

APPROVAL FOR THE SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM. THIS DEVICE IS INDICATED TO PROVIDE DEFIBRILLATION THERAPY FOR THE TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYARRHYTHMIAS INPATIENTS WHO DO NOT HAVE SYMPTOMATIC BRADYCARDIA, INCESSANT VENTRICULAR TACHYCARDIA, OR SPONTANEOUS, FREQUENTLY RECURRING VENTRICULAR TACHYCARDIA THAT IS RELIABLY TERMINATED WITH ANTITACHYCARDIA PACING.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Sep 28, 2012

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P110042
Regulatory pathway
Premarket approval application
Product code
LWS
Decision code
APPR
Decision date
Sep 28, 2012
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P110042 received

    Application receipt date recorded by FDA.

  2. P110042 · FDA decision

    APPR

  3. P110042/S216 · Related supplement

    EMBLEM Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) high voltage (HV) Capacitor

Timeline entries are records held by MedtechLedger for P110042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110042

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 2, 2026FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records